Efficacy and safety of pulsed intravenous methylprednisolone in early active thyroid eye disease

References

• Bahn RS. Graves’ ophthalmopathy. N Eng J Med. 2010;362(8):726–738. doi:10.1056/NEJMra0905750.
   PubMed Web of Science ®Google Scholar
• Wiersinga WM, Perros P, Kahaly GJ, et al. Clinical assessment of patients with Graves’ orbitopathy: the European Group on Graves’ Orbitopathy recommendations to generalists, specialists and clinical researchers. Eur J Endocrinol. 2006;155(3):387–389. doi:10.1530/eje.1.02230.
   PubMed Web of Science ®Google Scholar
• Shan SJ, Douglas RS. The pathophysiology of thyroid eye disease. J Neuroophthalmol. 2014;34(2):177–185. doi:10.1097/WNO.0000000000000132.
   PubMed Web of Science ®Google Scholar
• Wiersinga WM, Prummel MF. Pathogenesis of Graves’ ophthalmopathy: current understanding. J Clin Endocrinol Metab. 2001;86:501–503.
   PubMed Web of Science ®Google Scholar
• Smith TJ. Novel aspects of orbital fibroblast pathology. J Endocrinol Invest. 2004;27(3):246–253. doi:10.1007/BF03345273.
   PubMed Web of Science ®Google Scholar
• Bartalena L, Baldeschi L, Dickinson A, et al. Consensus statement of the European Group on Graves’ orbitopathy (EUGOGO) on management of GO. Eur J Endocrinol. 2008;158(3):273–285. doi:10.1530/EJE-07-0666.
   PubMed Web of Science ®Google Scholar
• Rundle FF, Wilson CW. Development and course of exophthalmos and ophthalmoplegia in Graves’ disease withspecial reference to thyroidectomy. Clin Sci. 1945;5:177–194.
   PubMed Web of Science ®Google Scholar
• Bartley GB. Rundle and his curve. Arch Ophthalmol. 2011;129(3):356–358. doi:10.1001/archophthalmol.2011.29.
   PubMedGoogle Scholar
• Menconi F, Profilo MA, Leo M, et al. Spontaneous improvement of untreated mild Graves’ ophthalmopathy. Rundle’s curve revisited. Thyroid. 2014;24(1):60–66. doi:10.1089/thy.2013.0240.
   PubMed Web of Science ®Google Scholar
• Kahaly GJ, Pitz S, Hommel G, Randomized DM. Single blind trial of intravenous versus oral steroid monotherapy in Graves’ orbitopathy. J Clin Endocrinol Metab. 2005;90(9):5234–5240. doi:10.1210/jc.2005-0148.
   PubMed Web of Science ®Google Scholar
• Prummel MF, Bakker A, Wiersinga WM, et al. Intravenous vs. oral steroids for Graves’ ophthalmopathy. J Clin Endocrinol Metab. 2005;90:5234–5240.
   PubMed Web of Science ®Google Scholar
• Bartalena L, Krassas GE, Wiersinga W. Efficacy and safety of three different cumulative disease of intravenous methylprednisolone for moderate to severe and active Graves’ orbitopathy. J Clin Endocrinol Metab. 2012;97:4454–4463. doi:10.1210/jc.2012-2389.
   PubMed Web of Science ®Google Scholar
• Sinha A, Bagga A. Pulse steroid therapy. Indian J Pediatr. 2008;75(10):1057–1066. doi:10.1007/s12098-008-0210-7.
   PubMed Web of Science ®Google Scholar
• Al-Habet SM, Rogers HJ. Methylprednisolone pharmacokinetics after intravenous and oral administration. Br J Clin Pharmacol. 1989;27:285–290.
   PubMed Web of Science ®Google Scholar
• Lim NC, Sundar G, Amrith S, Lee KO. Thyroid eye disease: a Southeast Asian experience. Br J Ophthalmol. 2015;99(4):512–518. doi:10.1136/bjophthalmol-2014-305649.
   PubMed Web of Science ®Google Scholar
• Mourits MP, Prummel MF, Wiersinga WM, Koornneef L. Clinical activity score as a guide in the management of patients with Graves’ ophthalmopathy. Clin Endocrinol (Oxf). 1997;47(1):9–14. doi:10.1046/j.1365-2265.1997.2331047.x.
   PubMed Web of Science ®Google Scholar
• International Thyroid Eye Disease Society. Clinical VISA recording forms. http://thyroideydisease.org/clinical-visa-recording-forms/.
   Google Scholar
• Mp M, Koornneef L, Wm W, et al. Clinical criteria for the assessment of disease activity in Graves’ ophthalmopathy: a novel approach. Br J Ophthalmol. 1989;73(8):639–644. doi:10.1136/bjo.73.8.639.
   PubMed Web of Science ®Google Scholar
• Marcocci C, Watt T, Altea MA, et al. Fatal and non-fatal adverse events of glucocorticoid therapy for Graves’ orbitopathy: a questionnaire survey among members of the European thyroid association. Eur J Endocrinol. 2012;166(2):247–253. doi:10.1530/EJE-11-0779.
   PubMed Web of Science ®Google Scholar
• Bahn RS. High-dose intravenous glucocorticoid therapy for Graves’ ophthalmopathy: where are we now? Thyroid. 2012;22:1–2. doi:10.1089/thy.2012.2201.ed.
   PubMed Web of Science ®Google Scholar
• Zang S, Ponto KA, Kahaly GH. Intravenous Glucocorticoids for Graves’ orbitopathy: efficacy and morbidity. J Clin Endocrinol Metab. 2011;96(2):320–332. doi:10.1210/jc.2010-1962.
   PubMed Web of Science ®Google Scholar
• Hart RH, Kendall-Taylor P, Crombie A, Perros P. Early response to intravenous glucocorticoids for severe thyroid-associated ophthalmopathy predicts treatment outcome. J Ocul Pharmacol Ther. 2005;21(4):328–336. doi:10.1089/jop.2005.21.328.
   PubMed Web of Science ®Google Scholar
• He Y, Mu K, Liu R, Zhang J, Xiang N. Comparison of two different regimens of intravenous methylprednisolone for patients with moderate to severe and active Graves’ ophthalmopathy: a prospective, randomized controlled trial. Endocr J. 2017;64(2):141–149. doi:10.1507/endocrj.EJ16-0083.
   PubMed Web of Science ®Google Scholar
• Suda T, Chida K, Matsuda H, et al. High-dose intravenous glucocorticoid therapy abrogates circulating dendritic cells. J Allergy Clin Immunol. 2003;112(6):1237–1239. doi:10.1016/j.jaci.2003.09.028.
   PubMed Web of Science ®Google Scholar
• Le Moli R, Baldeschi L, Saeed P, Regensburg N, Mourits MP, Wiersinga WM. Determinants of liver damage associated with intravenous methylprednisolone pulse therapy in Graves’ ophthalmopathy. Thyroid. 2007;17(4):357–362. doi:10.1089/thy.2006.0267.
   PubMed Web of Science ®Google Scholar
• Liu D, Ahmet A, Ward L, et al. A practical guide to the monitoring and management of the complications of systemic corticosteroid therapy. Allergy Asthma Clin Immunol. 2013;9(1):30. doi:10.1186/1710-1492-9-30.
   PubMed Web of Science ®Google Scholar
• Weissel M, Hauff W. Fatal liver failure after high-dose glucocorticoid pulse therapy in a patient with severe thyroid eye disease. Thyroid. 2000;10(6):521. doi:10.1089/thy.2000.10.11.
   PubMed Web of Science ®Google Scholar
• Marino´ M, Morabito E, Brunetto MR, Bartalena L, Pinchera A, Marocci C. Acute and severe liver damage associated with intravenous glucocorticoid pulse therapy in patients with Graves’ ophthalmopathy. Thyroid. 2004;14(5):403–406. doi:10.1089/105072504774193276.
   PubMed Web of Science ®Google Scholar
• Gust ID. Epidemiology of hepatitis B infection in the Western Pacific and South East Asia. Gut. 1996;38:S18–S23. doi:10.1136/gut.38.Suppl_2.S18.
   PubMed Web of Science ®Google Scholar